These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 18690965)

  • 1. Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends.
    Issa AM; Phillips KA; Van Bebber S; Nidamarthy HG; Lasser KE; Haas JS; Alldredge BK; Wachter RM; Bates DW
    Curr Drug Saf; 2007 Sep; 2(3):177-85. PubMed ID: 18690965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of new black box warnings and withdrawals for prescription medications.
    Lasser KE; Allen PD; Woolhandler SJ; Himmelstein DU; Wolfe SM; Bor DH
    JAMA; 2002 May; 287(17):2215-20. PubMed ID: 11980521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug withdrawals from the Canadian market for safety reasons, 1963-2004.
    Lexchin J
    CMAJ; 2005 Mar; 172(6):765-7. PubMed ID: 15767610
    [No Abstract]   [Full Text] [Related]  

  • 4. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
    Noah BA; Brushwood DB
    J Health Law; 2000; 33(3):383-454. PubMed ID: 11184355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    BMC Med; 2016 Feb; 14():10. PubMed ID: 26843061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals.
    Frank C; Himmelstein DU; Woolhandler S; Bor DH; Wolfe SM; Heymann O; Zallman L; Lasser KE
    Health Aff (Millwood); 2014 Aug; 33(8):1453-9. PubMed ID: 25092848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of factors related to the occurrence of important drug-specific postmarketing safety-related regulatory actions: A cohort study focused on first-in-class drugs.
    Ikeda J; Kaneko M; Narukawa M
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1393-1401. PubMed ID: 30094880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing drug safety and consequences of drug withdrawals.
    Mamdani M
    J Am Pharm Assoc (2003); 2004; 44(6):659-60. PubMed ID: 15637847
    [No Abstract]   [Full Text] [Related]  

  • 9. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
    Olivier P; Montastruc JL
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of FDA safety-related drug label changes in 2010.
    Lester J; Neyarapally GA; Lipowski E; Graham CF; Hall M; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):302-5. PubMed ID: 23280652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of regulatory guidances and drug regulation on risk minimization interventions in drug safety: a systematic review.
    Nkeng L; Cloutier AM; Craig C; Lelorier J; Moride Y
    Drug Saf; 2012 Jul; 35(7):535-46. PubMed ID: 22702638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reporting Adverse Drug Events.
    Feagins LA; Abdelsayed GG; Schairer J;
    Am J Gastroenterol; 2019 Sep; 114(9):1411-1413. PubMed ID: 31464745
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety of newly approved drugs: implications for prescribing.
    Temple RJ; Himmel MH
    JAMA; 2002 May; 287(17):2273-5. PubMed ID: 11980528
    [No Abstract]   [Full Text] [Related]  

  • 15. The FDA Drug Safety Bill: how safe are our drugs?
    Cobert B
    Expert Opin Drug Saf; 2008 Jul; 7(4):343-6. PubMed ID: 18613798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can pharmacogenetics help rescue drugs withdrawn from the market?
    Shah RR
    Pharmacogenomics; 2006 Sep; 7(6):889-908. PubMed ID: 16981848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.
    Pageot C; Bezin J; Smith A; Arnaud M; Salvo F; Haramburu F; Bégaud B; Pariente A;
    Drug Saf; 2017 Nov; 40(11):1099-1107. PubMed ID: 28664354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consistency in the safety labeling of bioequivalent medications.
    Duke J; Friedlin J; Li X
    Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):294-301. PubMed ID: 23042584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    Crit Rev Toxicol; 2016 Jul; 46(6):477-89. PubMed ID: 26941185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014.
    Pinnow E; Amr S; Bentzen SM; Brajovic S; Hungerford L; St George DM; Dal Pan G
    Clin Pharmacol Ther; 2018 Aug; 104(2):390-400. PubMed ID: 29266187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.